Want to see GB:IMM full AI Analyst Report?
Total Valuation
ImmuPharma has a market cap or net worth of £25.58M. The enterprise value is 20.22M .
Market Cap£25.58M
Enterprise Value20.22M
Share Statistics
ImmuPharma has 623,911,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding623,911,400
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ImmuPharma’s return on equity (ROE) is -2.63 and return on invested capital (ROIC) is -308.07%.
Return on Equity (ROE)-2.63
Return on Assets (ROA)-0.96
Return on Invested Capital (ROIC)-308.07%
Return on Capital Employed (ROCE)-3.70
Revenue Per Employee0.00
Profits Per Employee-258.24K
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ImmuPharma is ―. ImmuPharma’s PEG ratio is 0.44.
PE Ratio―
PS Ratio0.00
PB Ratio44.28
Price to FCF-12.84
Price to Operating Cash Flow-8.30
PEG Ratio0.44
Income Statement
In the last 12 months, ImmuPharma had revenue of 0.00 and earned -1.81M in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit-35.30K
Operating Income-2.54M
Pretax Income-2.17M
Net Income-1.81M
EBITDA-2.51M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -2.76M and capital expenditures -3.63K, giving a free cash flow of -2.77M billion.
Operating Cash Flow-2.76M
Free Cash Flow-2.77M
Free Cash Flow per Share>-0.01
Dividends & Yields
ImmuPharma pays an annual dividend of 1 p, resulting in a dividend yield of 17.86%
Dividend Per Share1 p
Dividend Yield17.86%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.03
52-Week Price Change-60.58%
50-Day Moving Average3.66
200-Day Moving Average4.93
Relative Strength Index (RSI)59.31
Average Volume (3m)1.99M
Important Dates
ImmuPharma upcoming earnings date is May 25, 2027, TBA (Confirmed).
Last Earnings DateSep 15, 2026
Next Earnings DateMay 25, 2027
Ex-Dividend Date―
Financial Position
ImmuPharma as a current ratio of 1.52, with Debt / Equity ratio of 0.00%
Current Ratio1.52
Quick Ratio1.52
Debt to Market Cap0.00
Net Debt to EBITDA0.54
Interest Coverage Ratio-214.45
Taxes
In the past 12 months, ImmuPharma has paid -364.50K in taxes.
Income Tax-364.50K
Effective Tax Rate0.17
Enterprise Valuation
ImmuPharma EV to EBITDA ratio is -11.59, with an EV/FCF ratio of -12.27.
EV to Sales0.00
EV to EBITDA-11.59
EV to Free Cash Flow-12.27
EV to Operating Cash Flow-12.28
Balance Sheet
ImmuPharma has £695.84K in cash and marketable securities with £0.00 in debt, giving a net cash position of £695.84K billion.
Cash & Marketable Securities£695.84K
Total Debt£0.00
Net Cash£695.84K
Net Cash Per Share<£0.01
Tangible Book Value Per Share<£0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ImmuPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast5.62%